Extended-release amantadine may improve levodopa dyskinesia control

VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine...
Source: Clinical Neurology News - Category: Neurology Source Type: news

Related Links:

Publication date: Available online 26 March 2020Source: Neuroscience LettersAuthor(s): Sini K. Koski, Sakari Leino, Pertti Panula, Saara Rannanpää, Outi Salminen
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Contributors : Shetty R DYAVAR ; Stella M PapaSeries Type : Expression profiling by arrayOrganism : Rattus norvegicusWe compared differential gene expression between Striatal tissue derived RNA isolated from Chronic Levodopa (L-DOPA) treated (L-Dopa methyl ester plus benserazide were given at 25 mg/kg and 6.25 mg/kg dose) -Parkinsonian and Dyskinetic Rats (LID Rats) for 8 days as compared to Parkinsonian Disease Control Rats (PD Control Rats). The hypothesis tested in the present study was that whether Inflammation has any role in Chronic Levodopa Induced Dyskinesia in Rats of Parkinson's disease model-as compared to Contr...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Rattus norvegicus Source Type: research
by Hiroshi Yoke, Hironori Ueno, Akihiro Narita, Takafumi Sakai, Kahoru Horiuchi, Chikako Shingyoji, Hiroshi Hamada, Kyosuke Shinohara Motile cilia/flagella are essential for swimming and generating extracellular fluid flow in eukaryotes. Motile cilia harbor a 9+2 arrangement consisting of nine doublet microtubules with dynein arms at the periphery and a pair of singlet microtubules at the center (central pair). In the central sy stem, the radial spoke has a T-shaped architecture and regulates the motility and motion pattern of cilia. Recent cryoelectron tomography data reveal three types of radial spokes (RS1, RS2, and RS...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
CONCLUSION: Continuous circadian i.c.v. of A-dopamine appears to be feasible and shows efficacy without dyskinesia with a safe therapeutic index. PMID: 32205254 [PubMed - as supplied by publisher]
Source: Neurobiology of Disease - Category: Neurology Authors: Tags: Neurobiol Dis Source Type: research
AbstractIstradefylline, a selective adenosine A2A receptor antagonist, has recently been approved for the treatment of ‘off’ episodes in patients with Parkinson’s disease (PD) who are already receiving treatment with levodopa/carbidopa. The aim of the article is to review the efficacy, safety and tolerability of istradefylline in the management of ‘off’ episodes of PD, based on English language articles on this topic indexed in PubMed or in the National Institute of Health clinical trials registry during 2003–2019. Based on the beneficial outcomes of phase 2 or 3 clinical trials and...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Airway clearance of pathogens and particulates relies on motile cilia. Impaired cilia motility can lead to reduction in lung function, lung transplant, or death in some cases. More than 50 proteins regulating cilia motility are linked to primary ciliary dyskinesia (PCD), a heterogeneous, mainly recessive genetic lung disease. Accurate PCD molecular diagnosis is essential for identifying therapeutic targets and for initiating therapies that can stabilize lung function, thereby reducing socioeconomic impact of the disease. To date, PCD diagnosis has mainly relied on nonquantitative methods that have limited sensitivity or re...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Resources Source Type: research
To explore the lived experience of chronic pain and dyskinesia in children and adolescents with cerebral palsy.
Source: BMC Pediatrics - Category: Pediatrics Authors: Tags: Research article Source Type: research
AbstractL-3,4-dihydroxyphenylalanine (L-DOPA) was introduced about half a century ago and is still the most effective medicine for the treatment of Parkinson ’s disease (PD). However, such chronic treatment eventually leads to L-DOPA-induced dyskinesia (LID) on the majority of PD patients. Besides L-DOPA, dopamine agonists are able to induce dyskinesia as well. So far no drug is yet claimed to effectively curb LID, and amantadine has only a modest bene fit on LID patients. Thus, understanding the molecular mechanisms behind LID is urgently needed, and developing new antiparkinsonian medications with low dyskinesia po...
Source: Neurological Sciences - Category: Neurology Source Type: research
This article is protected by copyright. All rights reserved. PMID: 32185794 [PubMed - as supplied by publisher]
Source: Clinical Genetics - Category: Genetics & Stem Cells Authors: Tags: Clin Genet Source Type: research
Authors: Endres D, Leypoldt F, Bechter K, Hasan A, Steiner J, Domschke K, Wandinger KP, Falkai P, Arolt V, Stich O, Rauer S, Prüss H, van Elst LT Abstract Primary schizophreniform psychoses are thought to be caused by complex gene-environment interactions. Secondary forms are based on a clearly identifiable organic cause, in terms of either an etiological or a relevant pathogenetic factor. The secondary or "symptomatic" forms of psychosis have reentered the focus stimulated by the discovery of autoantibody (Ab)-associated autoimmune encephalitides (AEs), such as anti-NMDA-R encephalitis, which can at...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
More News: Amantadine | Brain | Carbidopa/Levodopa | Dyskinesia | Neurology | Symmetrel